| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.09M | 4.14M | 4.6M | 4.94M |
| Revenue Growth % | - | - | - | - | - | - | - | 2.8% | 0.11% | 0.08% |
| Cost of Goods Sold | 0 | 0 | 92.78K | 93.94K | 183.09K | 0 | 545.89K | 2.73M | 3.5M | 3.24M |
| COGS % of Revenue | - | - | - | - | - | - | 0.5% | 0.66% | 0.76% | 0.65% |
| Gross Profit | 0 | 0 | -92.78K | -93.94K | -183.09K | 0 | 543.55K | 1.4M | 1.1M | 1.71M |
| Gross Margin % | - | - | - | - | - | - | 0.5% | 0.34% | 0.24% | 0.35% |
| Gross Profit Growth % | - | - | - | -0.01% | -0.95% | 1% | - | 1.58% | -0.22% | 0.55% |
| Operating Expenses | 1.84M | 3.44M | 6.69M | 10.39M | 8.97M | 12.17M | 14.34M | 9.78M | 9.24M | 9.62M |
| OpEx % of Revenue | - | - | - | - | - | - | 13.16% | 2.37% | 2.01% | 1.95% |
| Selling, General & Admin | 1.48M | 2.79M | 5.17M | 6M | 3.16M | 5.55M | 6.87M | 5.85M | 5.8M | 6.56M |
| SG&A % of Revenue | - | - | - | - | - | - | 6.3% | 1.41% | 1.26% | 1.33% |
| Research & Development | 292.84K | 573.72K | 1.52M | 4.3M | 5.81M | 6.62M | 7.28M | 3.73M | 3.22M | 2.85M |
| R&D % of Revenue | - | - | - | - | - | - | 6.68% | 0.9% | 0.7% | 0.58% |
| Other Operating Expenses | 67.41K | 75.22K | 0 | 94.72K | 0 | 0 | 185.66K | 202.25K | 219.6K | 212.84K |
| Operating Income | -1.84M | -3.44M | -6.78M | -10.36M | -9.15M | -12.17M | -13.79M | -8.38M | -8.13M | -7.92M |
| Operating Margin % | - | - | - | - | - | - | -12.66% | -2.03% | -1.77% | -1.6% |
| Operating Income Growth % | 0.47% | -0.87% | -0.97% | -0.53% | 0.12% | -0.33% | -0.13% | 0.39% | 0.03% | 0.03% |
| EBITDA | -1.77M | -3.36M | -6.69M | -10.26M | -8.97M | -12.02M | -13.28M | -7.78M | -7.53M | -7.38M |
| EBITDA Margin % | - | - | - | - | - | - | -12.19% | -1.88% | -1.64% | -1.49% |
| EBITDA Growth % | 0.48% | -0.9% | -0.99% | -0.53% | 0.13% | -0.34% | -0.1% | 0.41% | 0.03% | 0.02% |
| D&A (Non-Cash Add-back) | 67.41K | 75.22K | 89.6K | 94.72K | 183.09K | 149.84K | 511.79K | 596K | 604.52K | 534.73K |
| EBIT | -1.84M | -3.44M | -6.78M | -10.36M | -8.94M | -12.32M | -13.79M | -8.38M | -7.67M | -7.79M |
| Net Interest Income | 0 | 0 | 0 | 0 | 107.27K | -344.33K | 123.72K | 652.37K | 721.97K | -216.57K |
| Interest Income | 0 | 0 | 69.55K | 330.44K | 125.89K | 16.02K | 123.72K | 652.37K | 721.97K | 156.53K |
| Interest Expense | 48 | 495 | 0 | 0 | 18.62K | 360.35K | 0 | 0 | 0 | 373.11K |
| Other Income/Expense | -48 | -495 | 69.77K | 262.1K | 211.71K | -478.14K | -4.81M | 444.26K | 465.98K | -244.14K |
| Pretax Income | -1.84M | -3.44M | -6.71M | -10.1M | -8.94M | -12.65M | -18.6M | -7.93M | -7.67M | -8.16M |
| Pretax Margin % | - | - | - | - | - | - | -17.07% | -1.92% | -1.67% | -1.65% |
| Income Tax | 48 | 495 | 0 | -262.1K | 0 | 0 | 0 | 13.1K | 7.1K | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 0.99% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -1.84M | -3.44M | -6.71M | -10.01M | -8.94M | -12.65M | -18.6M | -7.95M | -7.68M | -8.16M |
| Net Margin % | - | - | - | - | - | - | -17.07% | -1.92% | -1.67% | -1.65% |
| Net Income Growth % | 0.47% | -0.87% | -0.95% | -0.49% | 0.11% | -0.42% | -0.47% | 0.57% | 0.03% | -0.06% |
| Net Income (Continuing) | -1.84M | -3.44M | -6.71M | -10.01M | -8.94M | -12.65M | -18.6M | -7.95M | -7.68M | -8.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -643.57 | -810.55 | -1032.30 | -1264.97 | -1161.21 | -938.91 | -21350.51 | -86.00 | -27.55 | -11.44 |
| EPS Growth % | 0.6% | -0.26% | -0.27% | -0.23% | 0.08% | 0.19% | -21.74% | 1% | 0.68% | 0.58% |
| EPS (Basic) | -643.57 | -810.55 | -1032.30 | -1264.97 | -1161.21 | -938.91 | -21350.51 | -86.00 | -27.55 | -11.44 |
| Diluted Shares Outstanding | 3.65K | 5.87K | 8.63K | 10.38K | 10.44K | 13.44K | 1.12K | 122.42K | 381.05K | 975.99K |
| Basic Shares Outstanding | 3.65K | 5.87K | 8.63K | 10.38K | 10.44K | 13.44K | 1.12K | 122.42K | 381.05K | 975.99K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 145.05K | 5.34M | 20.33M | 14.13M | 6.31M | 8.38M | 12.36M | 11.33M | 8.69M | 12.87M |
| Cash & Short-Term Investments | 41.92K | 5.16M | 20.13M | 13.74M | 5.85M | 7.41M | 8.01M | 8.91M | 6.57M | 11.08M |
| Cash Only | 41.92K | 5.16M | 18.35M | 9.81M | 5.81M | 7.36M | 7.95M | 8.91M | 6.57M | 11.08M |
| Short-Term Investments | 0 | 0 | 1.78M | 3.93M | 42.38K | 46.46K | 57.67K | 0 | 0 | 0 |
| Accounts Receivable | 65.79K | 45.48K | 40.58K | 64.74K | 45.34K | 11.92K | 113.31K | 260.4K | 352.84K | 465.1K |
| Days Sales Outstanding | - | - | - | - | - | - | 37.96 | 22.98 | 28.01 | 34.35 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 3.21M | 1.62M | 1.24M | 961.17K |
| Days Inventory Outstanding | - | - | - | - | - | - | 2.14K | 215.91 | 129.88 | 108.41 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 542.46K | 520.81K | 365.13K |
| Total Non-Current Assets | 1.13M | 1.07M | 1.01M | 944.96K | 1.49M | 1.4M | 4.11M | 2.77M | 3.13M | 2.71M |
| Property, Plant & Equipment | 3.65K | 20.8K | 42.38K | 42.53K | 403.49K | 326.6K | 1.16M | 723.43K | 1.25M | 992.2K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.94x | 5.72x | 3.68x | 4.98x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.13M | 1.05M | 968.42K | 902.44K | 1.09M | 1.06M | 2.71M | 1.95M | 1.78M | 1.62M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 14.65K | 227.38K | 104.91K | 100K | 100K |
| Total Assets | 1.28M | 6.41M | 21.34M | 15.07M | 7.8M | 9.78M | 16.46M | 14.11M | 11.82M | 15.58M |
| Asset Turnover | - | - | - | - | - | - | 0.07x | 0.29x | 0.39x | 0.32x |
| Asset Growth % | -0.05% | 4.02% | 2.33% | -0.29% | -0.48% | 0.25% | 0.68% | -0.14% | -0.16% | 0.32% |
| Total Current Liabilities | 456.17K | 284.24K | 713.02K | 1.19M | 1.68M | 2.22M | 4.27M | 2M | 1.97M | 1.84M |
| Accounts Payable | 253.97K | 284.24K | 713.02K | 1.56M | 0 | 775.13K | 1.5M | 544.18K | 626.19K | 370.14K |
| Days Payables Outstanding | - | - | 2.81K | 6.07K | - | - | 1K | 72.69 | 65.36 | 41.75 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | -372.38K | 1.61M | 880.21K | 643.64K | 558.48K | 488.28K | 490.4K |
| Current Ratio | 0.32x | 18.79x | 28.51x | 11.87x | 3.77x | 3.78x | 2.89x | 5.66x | 4.41x | 6.99x |
| Quick Ratio | 0.32x | 18.79x | 28.51x | 11.87x | 3.77x | 3.78x | 2.14x | 4.86x | 3.78x | 6.47x |
| Cash Conversion Cycle | - | - | - | - | - | - | 1.18K | 166.2 | 92.53 | 101.01 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 248.01K | 189.29K | 501.39K | 15.99K | 644.87K | 305.75K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 248.01K | 189.29K | 501.39K | 15.99K | 644.87K | 305.75K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Total Liabilities | 456.17K | 284.24K | 713.02K | 1.19M | 1.92M | 2.4M | 4.77M | 2.02M | 2.62M | 2.15M |
| Total Debt | 0 | 0 | 0 | 0 | 316.98K | 269.77K | 1.02M | 391.71K | 962.66K | 741.26K |
| Net Debt | -41.92K | -5.16M | -18.35M | -9.81M | -5.49M | -7.09M | -6.93M | -8.52M | -5.61M | -10.33M |
| Debt / Equity | - | - | - | - | 0.05x | 0.04x | 0.09x | 0.03x | 0.10x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -38340.98x | -6945.97x | - | - | -491.56x | -33.78x | - | - | - | -21.22x |
| Total Equity | 820.48K | 6.13M | 20.62M | 13.88M | 5.88M | 7.38M | 11.69M | 12.09M | 9.21M | 13.43M |
| Equity Growth % | -0.36% | 6.47% | 2.37% | -0.33% | -0.58% | 0.25% | 0.58% | 0.03% | -0.24% | 0.46% |
| Book Value per Share | 224.91 | 1044.22 | 2389.03 | 1336.99 | 563.00 | 548.89 | 10425.18 | 98.75 | 24.16 | 13.77 |
| Total Shareholders' Equity | 820.48K | 6.13M | 20.62M | 13.88M | 5.88M | 7.38M | 11.69M | 12.09M | 9.21M | 13.43M |
| Common Stock | 25.33M | 33.18M | 51.75M | 52.24M | 53.07M | 60.59M | 91.03M | 77.62M | 82.78M | 91.22M |
| Retained Earnings | -29.62M | -32.9M | -39.02M | -49.19M | -64.65M | -74.85M | -120.3M | -101.4M | -109.08M | -117.24M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 128.57K | 165.5K | 128.57K | 128.57K | 128.57K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -386.07K | -2.37M | -3.68M | -6.68M | -7.37M | -9.79M | -15.58M | -7.28M | -6.99M | -7.77M |
| Operating CF Margin % | - | - | - | - | - | - | -14.3% | -1.76% | -1.52% | -1.57% |
| Operating CF Growth % | 0.76% | -5.13% | -0.56% | -0.82% | -0.1% | -0.33% | -0.59% | 0.53% | 0.04% | -0.11% |
| Net Income | -1.84M | -3.44M | -6.71M | -10.1M | -8.94M | -10.2M | -18.6M | -7.95M | -7.68M | -8.16M |
| Depreciation & Amortization | 67.41K | 75.22K | -92.78K | 94.72K | 183.09K | 120.87K | 511.79K | 596K | 604.52K | 534.73K |
| Stock-Based Compensation | 695.2K | 1.17M | 2.43M | 3.11M | 0 | 610.19K | 697.89K | 278.15K | 137.71K | 119.31K |
| Deferred Taxes | 0 | 0 | -2.25M | 2 | 0 | -242.39K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 2.51M | -71.39K | 1.02M | 374.23K | 4.88M | 356.09K | 316.82K | 78.32K |
| Working Capital Changes | 688.73K | -165.8K | 431.4K | 283.89K | 358.11K | -450.45K | -3.07M | -565.82K | -369.34K | -337.17K |
| Change in Receivables | 0 | 0 | 4.55K | -24.08K | 17.27K | 40.2K | -40.01K | -219.15K | -92.44K | -114.69K |
| Change in Inventory | 0 | 0 | -431.94K | 0 | 0 | 0 | -2M | 565.56K | 66.22K | 283.15K |
| Change in Payables | 0 | 0 | 431.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -885 | -19.52K | -1.88M | -2.11M | 3.79M | -1.73K | -673K | -661.8K | -9.29K | 0 |
| Capital Expenditures | -885 | -19.52K | -43.8K | -27.04K | -42.57K | -1.73K | -39.11K | -161.8K | -9.29K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 0.04% | 0.04% | 0% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -17.02K | 0 | 0 | -425K | 0 | 0 | 0 |
| Cash from Financing | 300.14K | 7.5M | 19.27M | 272.5K | -30.99K | 10.85M | 15.07M | 10.68M | 4.65M | 12.27M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -4.54K | -764.62K | -1.02M | 64.93K | 0 | -1.62M | -1.78M | 646 | -561.98K | 4.14M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -386.96K | -2.38M | -3.72M | -6.71M | -7.42M | -9.79M | -15.62M | -7.45M | -7M | -7.77M |
| FCF Margin % | - | - | - | - | - | - | -14.34% | -1.8% | -1.52% | -1.57% |
| FCF Growth % | 0.76% | -5.16% | -0.56% | -0.8% | -0.11% | -0.32% | -0.6% | 0.52% | 0.06% | -0.11% |
| FCF per Share | -106.07 | -406.57 | -431.14 | -645.83 | -710.40 | -728.65 | -13936.54 | -60.81 | -18.36 | -7.96 |
| FCF Conversion (FCF/Net Income) | 0.21x | 0.69x | 0.55x | 0.67x | 0.82x | 0.77x | 0.84x | 0.92x | 0.91x | 0.95x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.1K | 7.1K | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -175.33% | -99.05% | -50.16% | -58.02% | -90.47% | -190.86% | -195.14% | -66.85% | -72.08% | -72.1% |
| Return on Invested Capital (ROIC) | -143.55% | -295.43% | -313.6% | -244.66% | -307.33% | -2713.96% | -410.45% | -150.95% | -170.27% | -177.35% |
| Gross Margin | - | - | - | - | - | - | 49.89% | 33.93% | 23.94% | 34.53% |
| Net Margin | - | - | - | - | - | - | -1707.32% | -192.18% | -166.94% | -165.14% |
| Debt / Equity | - | - | - | - | 0.05x | 0.04x | 0.09x | 0.03x | 0.10x | 0.06x |
| Interest Coverage | -38340.98x | -6945.97x | - | - | -491.56x | -33.78x | - | - | - | -21.22x |
| FCF Conversion | 0.21x | 0.69x | 0.55x | 0.67x | 0.82x | 0.77x | 0.84x | 0.92x | 0.91x | 0.95x |
| Revenue Growth | - | - | - | - | - | - | - | 279.61% | 11.18% | 7.5% |
InMed Pharmaceuticals Inc. (INM) reported $5.3M in revenue for fiscal year 2025.
InMed Pharmaceuticals Inc. (INM) grew revenue by 7.5% over the past year. This is steady growth.
InMed Pharmaceuticals Inc. (INM) reported a net loss of $8.9M for fiscal year 2025.
InMed Pharmaceuticals Inc. (INM) has a return on equity (ROE) of -72.1%. Negative ROE indicates the company is unprofitable.
InMed Pharmaceuticals Inc. (INM) had negative free cash flow of $7.5M in fiscal year 2025, likely due to heavy capital investments.